Pfizer withdraws dalbavancin applications

Pfizer (NYSE:PFE) withdrew an NDA in the U.S. and an MAA in Europe for dalbavancin

Read the full 154 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE